topotecan

The patient was treated on a non-protocol treatment plan with five cycles of vincristine, carboplatin, etoposide, cyclophosphamide, and weekly intraventricular topotecan via Ommaya reservoir, followed by autologous stem cell rescue. Optical genome mapping (OGM) showed that the proximal breakpoint of the balanced inversion at 13q14.2 was within intron 17 of RB1, while the distal breakpoint at 13q31.3 did not interrupt any known genes of clinical significance. We review the various molecular techniques that aided in diagnosis of this patient and provide a summary of similar RB1-disrupting structural variants reported in the literature.

Drug likeness analysis results revealed that chalcone derivatives CD5, CD8, and CD9 and reference standard drugs lorlatinib and topotecan showed no violations against all five drug likeness rules. Current study overcomes these challenges by employing green nanocatalysts (Al(OH)₃ and Ti/Fe@Al(OH)₃) for eco-friendly, high-yield synthesis and computational screening to design potent, multi-target lung cancer therapeutic chalcone compounds. The online version contains supplementary material available at 10.1007/s40203-026-00599-3.

P1, N=20, Recruiting, Washington University School of Medicine | Trial completion date: Nov 2026 --> Jun 2031 | Trial primary completion date: Aug 2026 --> Mar 2031

Preclinical studies indicate that pharmacological inhibition of SUMOylation with agents like TAK-981, topotecan, or Paromomycin reduces tumor growth, reverses therapy resistance, and enhances radiosensitivity. Moreover, SUMO-related enzymes, such as UBA2, SENP1, and SUMO2/3, may serve as prognostic biomarkers. Understanding SUMOylation in GBM offers insights into tumor biology and identifies potential therapeutic targets to improve patient outcomes.

P3, N=289, Recruiting, AstraZeneca | N=46 --> 289

P2/3, N=46, Not yet recruiting, AstraZeneca AB

P1, N=1, Terminated, Weill Medical College of Cornell University | Trial completion date: Dec 2026 --> Dec 2025 | Active, not recruiting --> Terminated; Study terminated due to low accrual

P1, N=18, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P3, N=450, Not yet recruiting, GlaxoSmithKline | Trial completion date: Jan 2030 --> Jul 2030 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Jan 2030 --> Jul 2030

Additionally, drug-likeness and pharmacokinetic properties, predicted by SwissADME, indicated that 5c complies with Lipinski's and Veber's rules of oral bioavailability showing a bioavailability score of 0.55. These findings highlight compound 5c as a promising Topo I inhibitor with mechanistically validated multimodal anticancer activity, superior inhibitory potency compared with topotecan, and enhanced selectivity toward cancer cells over normal CD8+ cells, supporting its potential for further anticancer drug development.

P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | N=60 --> 18 | Trial primary completion date: Apr 2027 --> Feb 2026

P1, N=60, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting